Literature DB >> 35965790

The diagnostic accuracy of TCT + HPV-DNA for cervical cancer: systematic review and meta-analysis.

Tao Li1,2, Yi Lai1,2, Jialing Yuan1,2.   

Abstract

Background: This study sought to systematically analyze the clinical diagnostic value of tumor markers combined with ThinPrep cytologic test (TCT) and human papillomavirus (HPV) deoxyribonucleic acid (DNA) detection for cervical cancer and pre-cancerous lesions. However, there is a lot of controversy in the field of TCT + HPV-DNA. Many people have mixed opinions on the accuracy of TCT + HPV-DNA, and there is no unified opinion. Therefore, it is necessary to further confirm the significance of this combined detection method in the early diagnosis of cervical cancer by applying meta method.
Methods: The Cochrane Library, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM) databases were searched to retrieve studies. To assess the methodological quality of each study and potential risk of bias, QUADAS-2 Guidelines were used to evaluate the quality of all articles that met the inclusion criteria and data extraction of the included articles were performed, and a meta-analysis was performed of the included studies using Review Manager 5.2 software.
Results: A total of 5 studies were included in the study, and a total of 2,778 patients were included in the study, and there was no significant publication bias observed. The meta-analysis showed that there was a statistical difference in terms of the accuracy of the tumor markers combined with TCT in the detection of cervical cancer. The results were as follows: the pooled sensitivity (SEN) was 0.86 (95% CI: 0.75-0.93); the combined specificity (SPE) was 0.79 (95% CI: 0.57-0.92); the diagnostic performance of combined with thin-layer liquid-based cytology and HPV DNA detection in the diagnosis accuracy of cervical cancer by summary receiver operating characteristic (SROC) curve analysis, result showed excellent diagnostic accuracy, with a combined area under the curve (AUC) of 0.90 (95% CI: 0.87-0.92). Discussion: Tumor markers are important for the early diagnosis of cervical cancer. Combining the tumor markers with TCT and HPV DNA detection effectively improved the detection rate. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Tumor marker; clinical diagnosis; human papillomavirus (HPV); thin-layer liquid-based cytology

Year:  2022        PMID: 35965790      PMCID: PMC9372687          DOI: 10.21037/atm-22-1732

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Cervical cancer is a gynecological malignant tumor whose incidence is only to that of breast cancer (1). Despite the widespread screening programs, cervical cancer remains the third most common cancer in developing countries (2). The early clinical symptoms of this disease are not typical, and it is easy to be missed and misdiagnosed clinically. In recent years, the incidence of cervical cancer has continued to increase, and thus it poses a serious threat to the health of patients (3). In recent years, the incidence of cervical cancer has been increasing year by year, as has the incidence among younger women (4). At the beginning of the disease, the patient’s clinical symptoms are not obvious, so the diagnostic accuracy is not high. To effectively prevent cervical cancer, it is generally accepted that the early detection of lesions is very important. At present, the application of serum tumor markers in the diagnosis of cervical cancer is increasing, but there is a lack of research on the diagnosis of cervical cancer (5). At present, many cervical disease screening techniques are widely used in clinical practice, among which human papillomavirus (HPV) examination and ThinPrep cytologic test (TCT) examination have relatively important clinical value. However, there is a lot of controversy in the field of TCT + HPV-DNA. Many people have mixed opinions on the accuracy of TCT + HPV-DNA, and there is no unified opinion (6-10). Therefore, it is necessary to further confirm the significance of this combined detection method in the early diagnosis of cervical cancer by applying meta method. We present the following article in accordance with the PRISMA-DTA reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-22-1732/rc).

Methods

Search strategy

According to the requirements of the Cochrane Collaboration, a computer search was conducted to retrieve all relevant articles published in The Cochrane Library, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM) databases. The English search words included cervical carcinoma, cervical lesion, cervical intraepithelial neoplasia, CIN, cervical disease, pre-cancerous cervical cancer, cervical cancer, cervix neoplasms, cervical screening, mass smear, liquid-based, thin-layer liquid-based cytology, Pap smear, Papanicolaou smear, cytology, cyto-diagnosis, cytological techniques, human papillomavirus, HPV, colposcopy, biopsy, and histological diagnosis. All the retrieved articles were manually re-screened ().
Figure 1

Flow chart of the literature screening process.

Flow chart of the literature screening process.

Literature inclusion criteria

To be eligible for inclusion in the meta-analysis, the articles had to meet the following inclusion criteria: (I) be an English-language article published; (II) include ≥20 subjects; (III) evaluate the value of the liquid-based cell test, and the HPV test, and the combined value of the 2 methods in cervical disease screening; (IV) be a retrospective cohort study; (V) use a positive criterion for the liquid-based cytology of atypical squamous cells of undetermined significance and above lesions; (VI) use the gold-standard pathological tissue diagnosis, and a positive diagnostic standard for cervical intraepithelial neoplasia I (CIN I) or above lesions; (VII) have complete original data that could be obtained directly or have available data from which the true positive number, false positive number, false negative number, and true negative number of the test could be obtained.

Literature exclusion criteria

Articles were excluded from the meta-analysis if they met any of the following exclusion criteria: (I) comprised a review, conference paper, lecture, or abstract; (II) had incomplete literature data; (III) the main purpose of the study was to examine a HPV vaccine, the HPV gene, HIV infection, or another topic; (IV) the cytological examination had been performed using the traditional pap smear method.

Data extraction and quality assessment

Two reviewers independently extracted the data included in the literature, which included the following: We extracted the following data for the diagnostic value of the author name, publication year, country, type of cancer, cancer stage. Quality assessment of diagnostic accuracy studies (QUADAS) was used for assessing quality of individual studies in this meta-analysis. This method is considered as an evidence-based quality assessment tool developed for use in systematic reviews. The highest score possible is 14.

Statistical method

Diagnostic sensitivity and specificity were calculated using the formulas: sensitivity = true positive/(true positive + false negative); and specificity = true negative/(true negative + false positive). The area under the receiver operating characteristic (ROC) curve was used to evaluate the feasibility of combined with thin-layer liquid-based cytology and HPV DNA detection in the diagnosis accuracy of cervical cancer. Publication bias was evaluated using Deeks’ funnel plot. Two-tailed P values of <0.05 were considered statistically significant. All statistical analysis was performed using Stata version 15.0. If I2>50% and P<0.1 from chi-square analysis showed study heterogeneity, Meta-analysis by random effects models and searched for possible heterogeneity by subgroup analysis source.

Results

Literature retrieval results and included research characteristics

In this study, the PubMed, Cochrane Library, Web of Science, Embase, CBM databases were searched. Repeated publications were excluded based on a reading of the titles and abstracts of the articles, after which 20 articles remained. Next, the full-text of the 20 articles were reviewed, and different reports of the same clinical study and articles inconsistent with the purpose of this study were excluded. Ultimately, a total of 5 studies were included in the study (11-15). All the retrieval and screening processes were completed independently by 2 evaluators, and any differences in opinions were resolved through internal discussion (). Almost all the literatures included in this study are within the effective range of the triangle, so there is no obvious risk bias.
Table 1

Basic clinical features of the 5 included studies

AuthorYearCountryType of cancerTumor/controlStage
Pan2019ChinaCervical intraepithelial neoplasia133/168CINI–III
Liang2016ChinaCervical intraepithelial neoplasia110/308CINI–III
Liu2017ChinaCervical cancer199/221CINI–III
Husaiyin2021ChinaCervical cancer477/1,145CINI–III
Zhang2020ChinaCervical cancer95/342CIN-III

Pooled diagnostic sensitivity and specificity

The diagnostic value of combined with thin-layer liquid-based cytology and HPV DNA detection in the diagnosis accuracy of cervical cancer from six studies. The results were as follows: the pooled sensitivity (SEN) was 0.86 (95% CI: 0.75–0.93); the combined specificity (SPE) was 0.79 (95% CI: 0.57–0.92): these results are illustrated by the forest map in .
Figure 2

Forest plot of pooled sensitivity and specificity of cervical cancer. Squares specify the effect sizes of individual studies and extended lines denote 95% CIs. Sizes of square imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. CI, confidence interval.

Forest plot of pooled sensitivity and specificity of cervical cancer. Squares specify the effect sizes of individual studies and extended lines denote 95% CIs. Sizes of square imply the weight of studies based on sample size using a random effects analysis. The diamond data indicates pooled prevalence. CI, confidence interval.

Pooled ROC curves

The diagnostic performance of combined with thin-layer liquid-based cytology and HPV DNA detection in the diagnosis accuracy of cervical cancer by summary receiver operating characteristic (SROC) curve analysis, result showed excellent diagnostic accuracy, with a combined area under the curve (AUC) of 0.90 (95% CI: 0.87–0.92) in .
Figure 3

The SROC curves of cervical cancer characteristics. SROC, summary receiver operating characteristic; AUC, area under the curve; SENS, sensitivity; SPEC, specificity.

The SROC curves of cervical cancer characteristics. SROC, summary receiver operating characteristic; AUC, area under the curve; SENS, sensitivity; SPEC, specificity.

Publication analysis

The Deeks’ Funnel plot shows that there is no publication bias, and shows that there is no publication bias in diagnostic studies.
Figure 4

Deeks’ funnel plot asymmetry test. ESS, standardized effect sizes.

Deeks’ funnel plot asymmetry test. ESS, standardized effect sizes.

Discussion

After breast cancer and colorectal cancer, cervical cancer is the 3rd most common malignant tumor in women worldwide, and the most common malignant tumor of the female reproductive tract (16). In 2021, there were 529,800 new cervical cancer cases and 255,100 deaths, with 85% of the new cases occurring in developing countries (17). Due to advances in cervical cancer screening technology, the incidence and mortality of cervical cancer in developed and developing countries have decreased significantly and become hot (18). The formation of cervical cancer is a continuous development process. CIN usually proceeds as follows: CIN I → CIN II → CIN III → carcinoma in situ (CIS) → early invasive carcinoma of the cervix → invasive carcinoma of the cervix. The time from CIN lesions to CIS of the cervix is 3–8 years (19). Due to the long, reversible pre-cancerous lesion stage in the occurrence and development of cervical cancer, with timely detection and appropriate treatment, the cure rate of early cervical cancer is nearly 100% (20). Thus, more and more attention has been paid to the early screening of cervical diseases in clinical practice, and more effective and reasonable examination methods have been developed to improve the accuracy of cervical disease diagnosis (21). Cervical cancer is the only gynecological cancer that can be diagnosed early and cured, and the early detection of pre-cancerous lesions is the key link in the prevention and treatment of cervical cancer (22-25). Traditional cervical cancer screenings are aimed at the early detection of cervical cancer, while modern cervical cancer screenings are aimed at the early detection of high-grade CIN lesions and the early treatment of obstructive cervical cancer. Cervical cancer is a popular area of modern medical research. Cervical cancer is an infectious disease caused by HPV infection. The development process for the formation of cervical cancer is continuous. The period from CIM to cervical cancer ranges from 3–8 years (26). Thus, the pre-screening of cervical cancer is particularly important. However, research needs to be conducted to determine which test is the most valuable for cervical disease screening. Extensive research has been conducted on disease screening technology for cervical disease, and based on traditional literature reviews, the research has 2 main characteristics. First, research results is the certain result of the literature more less number of come to the conclusion that generally do not evaluate the literature, also does not consider the quality of the literature. Second, there are 2 main problems; that is, the quality of many similar studies is not the same, and the number of samples in each study differs. Under the equal-weight method, which is used in traditional literature reviews, it is difficult to ensure the authenticity, reliability and scientific nature of research results, especially when the results of multiple studies are inconsistent, and any conclusions drawn may easily lead to misunderstandings or confusion (27). The statistical purpose of a meta-analysis is to merge, analyze, and summarize the results of similar independent research, increase the sample size, increase the efficiency of the inspection, examine inconsistent results, especially when multiple research studies have been conducted or the results are not statistically significant, and reveal the real situation based on a statistical analysis of the results. The present study had a number of limitations. First, the search of the databases was not sufficiently extensive. The multi-person, blind-screening method was not adopted in the search and screening of the articles, which may have led to the omission of some articles conforming to the standard. The authors of this study screened the articles according to the inclusion criteria and exclusion criteria, which may be subjective. Second, the unpublished article was not available. Third, only articles published in English were included in the meta-analysis. Due to the influence of language and region, articles in other languages and some unpublished studies were not included in the meta-analysis. The possibility of language bias or publication bias is large. As for some of the published articles, they were not included in the meta-analysis, as the original authors could not be contacted and the complete data were unavailable, which affected the comprehensive quality of the analysis. All the above-mentioned reasons may have led to sampling bias in this study. Future studies need to improve on the above-mentioned aspects to ensure the research results are more comprehensive and reliable and thus can be used to guide clinical applications. TCT is a thin-layer liquid-based cytology detection system for detecting cervical cells and conducting cytological classification diagnoses. Compared to a traditional pap smear, TCT has a higher detection rate, and thus can provide a pathological basis for the early diagnosis and treatment of cervical cancer, which in turn could reduce the death rate of cervical cancer patients. Pap smears must be performed by experienced and highly skilled laboratory personnel to ensure their accuracy. These methods have been widely used in the clinical screening of cervical cancer, but the detection rate of each method alone needs to be improved. This study examined the diagnostic value of the combined application of various indicators for cervical cancer. The results showed that the diagnostic value of the combined detection methods was far superior to that of a single detection method, and the detection value of HPV deoxyribonucleic acid (DNA) was higher than those of other detection methods. Thus, combined detection represents the best screening choice for individuals with the economic ability to pay for this type of screening. The article’s supplementary files as
  27 in total

1.  The clinical research of Thinprep Cytology Test (TCT) combined with HPV-DNA detection in screening cervical cancer.

Authors:  Y Liu; L Zhang; G Zhao; L Che; H Zhang; J Fang
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2017-02-28       Impact factor: 1.770

Review 2.  Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.

Authors:  P J Maver; M Poljak
Journal:  Clin Microbiol Infect       Date:  2019-09-17       Impact factor: 8.067

Review 3.  Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.

Authors:  Sharmila A Pimple; Gauravi A Mishra
Journal:  Minerva Ginecol       Date:  2019-10

Review 4.  Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

Authors:  Rafael Molina; Vivian Barak; Arie van Dalen; Michael J Duffy; Roland Einarsson; Massimo Gion; Helenka Goike; Rolf Lamerz; Marius Nap; György Sölétormos; Petra Stieber
Journal:  Tumour Biol       Date:  2005 Nov-Dec

5.  Detection of HPV E6/E7 mRNA in the diagnosis of cervical cancer and precancerous lesions after kidney transplantation.

Authors:  Jing Sun; Yanna Yue; Rong Li; Qian Sun; Chaofeng Hu; Xiaohong Ge; Qingyan Guan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

6.  The effect of local photodynamic therapy with 5-aminolevulinic acid in the treatment of vaginal intraepithelial lesions with high-risk HPV infection.

Authors:  Ting Zhang; Rui Hu; Yujie Tang; Yingcui Zhang; Lihong Qin; Yan Shen; Bingjie Wang; Luoman Zhang; Lili Cao; Yingying Zhou; Yuehui Su; Mengzhen Zhang
Journal:  Photodiagnosis Photodyn Ther       Date:  2022-01-16       Impact factor: 3.631

7.  Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Authors:  Marc Brisson; Jane J Kim; Karen Canfell; Mélanie Drolet; Guillaume Gingras; Emily A Burger; Dave Martin; Kate T Simms; Élodie Bénard; Marie-Claude Boily; Stephen Sy; Catherine Regan; Adam Keane; Michael Caruana; Diep T N Nguyen; Megan A Smith; Jean-François Laprise; Mark Jit; Michel Alary; Freddie Bray; Elena Fidarova; Fayad Elsheikh; Paul J N Bloem; Nathalie Broutet; Raymond Hutubessy
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  HPV-related methylation-based reclassification and risk stratification of cervical cancer.

Authors:  Si Yang; Ying Wu; Shuqian Wang; Peng Xu; Yujiao Deng; Meng Wang; Kang Liu; Tian Tian; Yuyao Zhu; Na Li; Linghui Zhou; Zhijun Dai; Huafeng Kang
Journal:  Mol Oncol       Date:  2020-06-02       Impact factor: 6.603

9.  Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening.

Authors:  Hui Liang; Min Fu; Jian Zhou; Lei Song
Journal:  Oncol Lett       Date:  2016-06-02       Impact factor: 2.967

10.  Triage human papillomavirus testing for cytology-based cervical screening in women of different ages in primary hospitals: A retrospective clinical study.

Authors:  Yuan-Yuan Zhang; Xiao-Qin Xu; Dan Zhang; Jie Wu; Hong-Xiu Zhang
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.